Drug Profile


Alternative Names: Asulacrine; Asulacrine isethionate; CI 921; NSC 343499; SN 21407

Latest Information Update: 02 Jul 1999

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Auckland Cancer Society Research Centre
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Cytostatics; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 02 Jul 1999 Discontinued-II for Cancer in New Zealand (IV-infusion)
  • 02 Jul 1999 Discontinued-II for Cancer in USA (IV-infusion)
  • 18 Jun 1999 Discontinued-I for Cancer in United Kingdom (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top